In prostate cancer, the translocation of eNOS to the nucleus has been identified as a relevant indicator of adverse clinical outcomes, a process in which nucleoporin 153 (Nup153) could play an important role since, recently, it has been identified as a regulator of the nuclear translocation of eNOS and ERβ in response to estrogen signaling [296]. This evidence concerns the gene NOS3 and prostate carcinoma.